Category Archives: Corporate

Novartis gets FDA nod for breakthrough leukemia treatment Kymriah; with a cost of $450,000, who’s going to get it?

The News: Novartis AG (Basel CHE) has obtained approval from the US Food and Drug Administration (FDA) for its Kymriah (tisagenlecleucel or CTL019) to treat children and young adults with… Read more »

Intra-Cellular shares zoom higher; is buying this name a gamble or a rational bet?

The News: Intra-Cellular Therapies Inc. (Nasdaq:ITCI) rocketed 41% over the past week to $15.70 on a positive regulatory update from the US Food and Drug Administration regarding its lumateperone treatment for schizophrenia…. Read more »

Winners outpace losers in wild week for healthcare stocks; my picks and pans.

Leading the largest pack of winners in quite a while, XOMA Corp. (Nasdaq:XOMA) soared $5.64, or 48% over the week, to $11.10, after the company revealed an agreement to out-license… Read more »

Pfizer granted Prevnar patent from India; drugmaker draws quick fire for pricing, access.

The News: India has granted Pfizer Inc. (NYC) a patent for its powerful pneumonia vaccine Prevenar 13, in a blow to some health groups that said this would put the… Read more »

Alexion on a roll as Soliris gets label expansion in EU; although flying under the radar, analysts, investors still bullish.

The News: Alexion Pharmaceuticals Inc. (New Haven CT) got another shot in the arm this week with the EU approving its key revenue driver Soliris for an additional indication. EU approval… Read more »

Merck’s Frazier leads the way quitting Trump business council after Charlottesville; J&J’s Gorsky’s bail way too late.

The News: One day after J&J chief exec Alex Gorsky pub­licly com­mit­ted to stay­ing on Pres­i­dent Don­ald Trump’s man­u­fac­tur­ing coun­cil, he abruptly re­versed course–just as the sud­den mass departure of ex­ec­u­tives forced… Read more »

Centene rescuing Obamacare as just two US counties still lack insurers for 2018.

The News: Centene Corp. (St. Louis MO) on Tuesday (August 15, 2017) said it will sell Obamacare plans in Nevada’s remaining 14 “bare” counties in 2018. The insurer previously announced… Read more »

Zynerba sinks twice as cannabis trials flop; strike three looms, so where’s the Ouija board?

The News: Zynerba Pharmaceuticals Inc. (ZYNE) lost more than half its value last week to $7.03 after the drug developer said its synthetic cannabis-based gel for epilepsy failed a mid-stage… Read more »

Kite submits IND for CAR-T multiple myeloma treatment; Novartis keeping wary eye on rival’s latest move in high-stakes race.

The News: Kite Pharma Inc. (Santa Monica CA) said it has submitted to the FDA an Investigational New Drug (IND) application to launch a Phase 1, first-in-human trial of a… Read more »

Endo coming out of the darkness into the light; contrarians, buy this name.

The News: Endo International Plc (Dublin IRL) on Tuesday (August 8, 2017) lowered its full-year revenue forecast, saying it expected lower sales of branded drugs to add to the pricing… Read more »